Phorbol esters, which activate protein kinase C, modulate vasoconstrictor-induced tension in vascular smooth muscle. We examined the effects of phorbol esters (phorbol 12,13- (second-order) branch of the superior mesenteric artery (SMA). PDBu and TPA significantly augmented agonist-evoked contractions in aorta but diminished those in SMA. For example, 30 nM PDBu increased 5-HIT-and AVP-evoked contractions 2.0-2.5-fold in aorta (p<0.01) but decreased 5-HIT-and AVPinduced contractions by 40-60%o in SMA (p< 0.01). In contrast, PDBu and TPA amplified high K+-and 10 mM caffeine-induced contractions in both aorta and SMA. Augmentation of agonist-induced contractions by PDBu was greater in endothelium-denuded aorta than in intact aorta. Two protein kinase C antagonists, H-7 and staurosporine, inhibited 5-HT-evoked contractions in the absence as well as in the presence of PDBu in both types of arteries. The augmentation of contractile responses to caffeine and K' by phorbol esters in both types of arteries suggests that the phorbols increase the sensitivity of the contractile apparatus to Ca2+, probably by activating protein kinase C. However, the inhibitory effects of phorbols on 5-Hr-and AVP-evoked responses in SMA suggest that under these conditions the dominant effect of the phorbols is a marked reduction in the availability of Ca21 in the SMA but not in the aorta. 
In high K' solution (e.g., 30 mM K' PSS), the NaCI in the standard PSS was replaced, mole for mole, by KCl. In Ca2+-free PSS, the CaCl2 was replaced by equimolar MgCl2. All solutions were adjusted to pH 7.4 with 2 M Tris.
Acetylcholine, caffeine, 5-HT, phenylephrine, phorbol 12,13-dibutyrate (PDBu), 12-O-tetradecanoylphorbol 13-acetate (TPA), staurosporine (a PKC inhibitor33), and 1-(5 -isoquinolinylsulfonyl)-2-methylpiperazine (H-7, also a PKC inhibitor34) were purchased from Sigma Chemical Co., St. Louis, Mo.; 4-a-PDBu was obtained from LC Services Corp., Woburn, Mass.; AVP was purchased from Peninsula Laboratories, Belmont, Calif.; and verapamil was a gift from Knoll Pharmaceuticals, Whippany, N.J. All drug solutions were prepared on the day of use. The 5 -HT and AVP were made as concentrated stock solutions in distilled water; PDBu and 4-a-PDBu were made as 1 mM stock solutions in 10% dimethyl sulfoxide; TPA and staurosporine were made as 10 and 1 mM stock solutions, respectively, in 100% dimethyl sulfoxide; H-7 and phenylephrine were made as 10 mM stock solutions in distilled water; acetylcholine was prepared as a 1 M stock solution in distilled water; and verapamil and caffeine were dissolved directly in PSS. The final concentration of dimethyl sulfoxide in PSS was less than 0.006%.
Contraction Measurements
Two thin (0.3-mm diameter) stainless-steel hooks were inserted through the lumen of the aortic rings; tungsten wire hooks (0.1-mm diameter) were used for SMA rings. One hook was fixed to the bottom of the tissue chamber (volume, 0.75 ml), and the other hook was connected to an isometric force transducer (model 52-9529, Harvard Apparatus, South Natick, Mass.), which was mounted directly above the tissue chamber. Isometric tension was continuously monitored and recorded on a strip-chart recorder. The tissue was continuously superfused at a rate of 2 ml/min with welloxygenated incubation fluid at 37°C. The arteries were equilibrated until the resting tension of aorta and SMA stabilized at 500 mg and 300 mg, respectively; this took 1.5-2.0 hours or more.
Most drugs and other reagents were added directly to the superfusion fluids and were therefore equilibrated in the tissue chamber. However, 5-HT and AVP were usually applied as small bolus injections (15 ,ul) Figure 2 . In both types of rings, PDBu induced a dose-dependent increase in resting tension. The absolute increases in resting tension in the SMA rings were small at low PDBu concentrations. When expressed on a wet weight basis, however, the increments in SMA resting tension were much larger than in the aortic rings: 169.8±51.4 (n=11) mg/mg wet wt for SMA and 23.7+5.7 (n=12) mg/mg wet wt for aorta with 30 nM PDBu. Furthermore, in control PSS, the SMA was more sensitive to 5-HT than was the aorta from the same rat (Figure 2 ; see References 37 and 38); i.e., the 5-HT dose-response curve for the SMA was located to the left of the comparable curve for the aorta (Figure 6 ). The SMA was also more sensitive to AVP than was the aorta.37 '38 In contrast to the activating effects of the phorbols on vasoconstrictor-evoked contractions in aortic rings, both PDBu (Figures 2, 4 , and 7) and TPA (Figures 4 and 7) significantly and reversibly inhibited the 5-HT-and AVP-evoked contractions in rings of SMA. As shown in Figure 6 , PDBu shifted the 5-HT dose-response curve to the right and downward in SMA and to the left in aortic rings; in the aorta in the presence of PDBu, however, this 5-HT-evoked tension in the aorta was superimposed on a progressively rising baseline tension.
This marked difference between the aorta and SMA was not due to the brevity of exposure to the vasoconstrictor; PDBu also increased 5-HT-evoked tension in the aorta ( Figure 8A ) but reduced the active tension in the SMA ( Figure 8B ) when the rings were exposed to submaximal concentrations of the agonist for a more prolonged period. 5 -HT and AVP in the presence of PDBu and TPA; these effects of H-7 were reversible. Similar effects of H-7 on PDBu-and receptor agonist-activated contractions were also observed in rings of SMA (not shown).
Even in the absence of phorbol esters, however, H-7 reversibly inhibited the contractile responses evoked by 5-HT ( Figure 9A ). The 5-HT dose-response curves ( Figures 9B and 9C) The data were obtained from six experiments similar to the one illustrated in panel A; data are normalized to the tension evoked by 60 ftM 5-HT before the introduction ofH-7 (=100%). Open circles indicate the mean of data from all six rings; solid (3 ,uM) and open (10 ,uM) however, 10 mM K' produced a small rise in tension and 15 mM K' evoked a substantial contraction; moreover, the contractile response to 20 mM K' was greatly augmented. These effects of PDBu were reversible.
PDBu also augmented K'-evoked contractions in rings of SMA. Figure 12B shows that PDBu increased the 30 mM K'-evoked contraction even though it attenuated the response to 5-HT in the same arterial ring. These effects of PDBu were completely reversible.
Data from a number of experiments similar to the ones illustrated in Figure 12 are summarized in Figure  13 . While SMA rings were much more sensitive to 5 -HT than aortic rings were (Figure 6 ), the aortic rings and SMA rings were equally sensitive to high [K+]0; that is, as shown in Figure 13 Phorbol esters produce slowly developing and longlasting contractions in unstimulated VSM.17-20 The mechanism underlying these contractions is uncertain, although data from permeabilized VSM preparations demonstrate that the sensitivity of the contractile apparatus to Ca24 is increased (i.e., the relation between PDBu opens Ca24 channels directly,47 thereby promoting rapid Ca2' entry43 that is soon counterbalanced by enhanced Ca2' extrusion,44 although release and resequestration of Ca2' by the SR cannot be ruled out. Nevertheless, these data suggest that the contribution of Ca2' influx to the phorbol ester-induced rise in steady tension may be relatively small. In agreement with previous reports,5'17'39 however, we observed inhibition of phorbol ester-induced contractions in unstimulated aortic rings on removal of extracellular Ca2' or addition of the Ca2' channel blocker verapamil ( Figure 3) . Therefore, these phorbol ester- 
Conclusions
Augmentation of receptor agonist-induced contractions by PDBu in rat aorta cannot be attributed to enhanced receptor activation or to enhanced Ca'4 transients but rather primarily to the increased sensitivity of contractile elements to the available Ca'+ that apparently results from activation of PKC. The seemingly paradoxical inhibition of receptor agonist-activated contractions in SMA raises the possibility that phorbol esters may act preferentially to downregulate the receptor-activated rise in [Ca'+]J in these vessels.
The apparent differences in the effects of phorbol esters on agonist-activated tension in different blood vessels713"5-17,48,56 (this report) may be explained by the complex interrelations involved in tension development that depend on 1) the fraction of receptors that are activated, 2) the availability of Ca2+ (from the extracellular fluid and the SR stores), and 3) the sensitivity of the contractile apparatus to that Ca24. PKC may modulate all three of these processes, and the relative effects may be quantitatively different in different blood vessels. Therefore, activation of PKC may lead to augmented receptor agonist-activated contractions in some vessels and depressed receptor agonist-activated contractions in others. The depression of contraction seems to involve multiple agonistspecific receptors (e.g., 5-HT and AVP receptors, as in this study, and norepinephrine receptors, as in the study of Salaices and coworkers56). Therefore, it seems likely that a common factor is involved, perhaps the uncoupling of the receptors from G proteins, but this needs to be tested directly. 
